A5087798311- Reproductive Biology and Fertility
- Reproductive Health and Technologies
- Ovarian cancer diagnosis and treatment
- Uterine Myomas and Treatments
- Cervical Cancer and HPV Research
- Endometriosis Research and Treatment
- Diversity and Career in Medicine
- Maternal and Perinatal Health Interventions
- Pregnancy-related medical research
- BRCA gene mutations in cancer
- Ovarian function and disorders
- LGBTQ Health, Identity, and Policy
- Maternal and fetal healthcare
- Ectopic Pregnancy Diagnosis and Management
- Reproductive Health and Contraception
- Global Cancer Incidence and Screening
- Electrolyte and hormonal disorders
- Family and Patient Care in Intensive Care Units
- COVID-19 and healthcare impacts
- Pregnancy and Medication Impact
- Reproductive System and Pregnancy
- Blood donation and transfusion practices
- HIV/AIDS Research and Interventions
- Sexuality, Behavior, and Technology
- Prenatal Screening and Diagnostics
Icahn School of Medicine at Mount Sinai
2020-2025
Mount Sinai Hospital
2024
New York University
2020
Cornell University
2020
In April 2020, in light of COVID-19-related blood shortages, the US Food and Drug Administration (FDA) reduced deferral period for men who have sex with (MSM) from its previous duration 1 year to 3 months.Although originally born out necessity, decades-old restrictions on MSM donors been mitigated by significant advancements HIV screening, treatment, public education. The severity ongoing COVID-19 pandemic-and urgent need safe products respond such crises-demands an immediate reconsideration...
To evaluate fertility treatment outcomes among transgender (TG) men with a history of gender-affirming hormone therapy exogenous testosterone.
Previvors are becoming more aware of the option risk-reducing salpingectomy with delayed oophorectomy (RRS-DO) to mitigate their risk ovarian cancer. In this qualitative study, we explored clinical and non-clinical factors that impacted previvors' decision-making pursue RRS-DO as a reduction strategy.Semi-structured telephone interviews were conducted previvors transcribed verbatim. Using ATLAS.ti® software, two primary investigators interpreted data through thematic analysis. After coding...
Placenta previa is diagnosed in up to 15% of pregnancies at the anatomy ultrasound and 0.5% persist term. There limited data regarding pregnancy outcomes with resolved previa. We aimed examine patients placenta determine if abnormal placentation any time during associated adverse events labor.Patients were identified after second trimester ultrasound, included placental edge greater than 2 cm from internal cervical os, excluded persisted term, resolution occurred prior 20 weeks, underwent a...